You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: 7,001,602


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,001,602
Title:Use of botulinum toxin therapy for urinary incontinence and related disorders
Abstract: The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s): Schmidt; Richard A. (Arvada, CO)
Assignee: The Regents of the University of Colorado (Boulder, CO)
Application Number:10/685,995
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 7,001,602

Introduction

When evaluating the claims and patent landscape of a specific patent, such as United States Patent 7,001,602, it is crucial to delve into several key areas. These include the patent's claims, the prior art, the novelty and non-obviousness of the invention, and the broader patent landscape. Here, we will conduct a comprehensive and critical analysis of these aspects.

Understanding the Patent Claims

To begin, it is essential to understand what the patent claims cover. The claims of a patent define the scope of the invention and are the basis for determining infringement and validity.

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[3].

Claim Interpretation

The interpretation of claims is critical. Claims must be interpreted under their broadest reasonable construction to determine their scope. This involves identifying the elements of the claim and ensuring that any prior art reference teaches every element as set forth in the claim[3].

Prior Art and Anticipation

Prior art plays a significant role in determining the validity of a patent. Under 35 U.S.C. § 102, a claimed invention may be rejected if it is anticipated by prior art.

Definition of Anticipation

A claim is anticipated if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference. For example, if a prior art reference discloses a range that overlaps or touches the claimed range, it must do so with sufficient specificity to constitute an anticipation[3].

Example from US2292387A

The secret communication system patented by Hedy Kiesler Markey and George Antheil (US2292387A) illustrates how prior art can impact patent validity. This patent involves a method of secret communication using carrier waves of different frequencies. If a later patent (like US7,001,602) were to claim a similar method without significant differentiation, it could be anticipated by this prior art[1].

Novelty and Non-Obviousness

For a patent to be valid, the invention must be novel and non-obvious.

Novelty

Novelty requires that the invention be new and not anticipated by prior art. This means that no single prior art reference can teach every element of the claimed invention[3].

Non-Obviousness

Non-obviousness requires that the invention be significantly different from existing technology. If the differences between the claimed invention and the prior art are such that they would have been obvious to one of ordinary skill in the art, the patent may be invalid[3].

Patent Landscape Analysis

The patent landscape includes all existing patents and patent applications related to the same or similar technologies.

Competitive Analysis

Analyzing the patent landscape helps in understanding the competitive environment. It reveals who else is working in the same field, what technologies they are developing, and how they might impact your patent.

Example of Patent Landscape in Communication Systems

In the field of communication systems, patents like US2292387A (secret communication systems) and others related to frequency hopping or secure communication methods can influence the validity and enforceability of later patents. For instance, if US7,001,602 involves advancements in secure communication, it must be differentiated from earlier patents to avoid anticipation or obviousness issues[1].

Critical Analysis of US7,001,602

Claim Specificity

To critically analyze US7,001,602, one must examine the specificity of its claims. Are the claims broad and vague, or are they narrowly tailored to a specific invention? Broad claims are more likely to be anticipated by prior art, while narrow claims may avoid anticipation but risk being obvious.

Prior Art Review

A thorough review of prior art is essential. This includes searching for patents, academic papers, and other publications that may disclose similar inventions. For example, if US7,001,602 involves frequency hopping techniques, a review of earlier patents like US2292387A would be necessary to ensure that the new patent does not merely replicate existing technology.

Industry Expert Insights

Industry experts can provide valuable insights into whether the invention is novel and non-obvious. Their opinions can help in understanding whether the differences between the claimed invention and prior art are significant enough to warrant patent protection.

Case Studies and Examples

Frequency Hopping Techniques

If US7,001,602 involves frequency hopping techniques, it would be crucial to differentiate it from earlier patents like US2292387A. For instance, if the new patent introduces a novel method of synchronizing frequency changes or enhances security through additional layers of encryption, these differences would need to be clearly articulated in the claims and specification.

Regulatory and Legal Considerations

USPTO Guidelines

The United States Patent and Trademark Office (USPTO) provides guidelines for evaluating novelty and non-obviousness. These guidelines, such as those outlined in the Manual of Patent Examining Procedure (MPEP), are crucial for understanding how the USPTO will evaluate the patent claims[3].

Court Precedents

Court precedents also play a significant role. Cases like Verdegaal Bros. v. Union Oil Co. of California and UCB, Inc. v. Actavis Labs. UT, Inc. provide guidance on what constitutes anticipation and non-obviousness[3].

Key Takeaways

  • Claim Specificity: Ensure that patent claims are specific and narrowly tailored to avoid anticipation issues.
  • Prior Art Review: Conduct a thorough review of prior art to ensure the invention is novel and non-obvious.
  • Industry Insights: Seek opinions from industry experts to validate the novelty and non-obviousness of the invention.
  • Regulatory Compliance: Adhere to USPTO guidelines and consider court precedents when evaluating patent claims.

FAQs

Q: What is the significance of prior art in patent evaluation? A: Prior art is crucial in determining whether a patent is novel and non-obvious. It must be reviewed to ensure that the claimed invention is not anticipated by existing disclosures.

Q: How do you determine if a claim is anticipated by prior art? A: A claim is anticipated if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference[3].

Q: What is the difference between novelty and non-obviousness? A: Novelty requires that the invention be new and not anticipated by prior art, while non-obviousness requires that the invention be significantly different from existing technology[3].

Q: Why is it important to analyze the patent landscape? A: Analyzing the patent landscape helps in understanding the competitive environment and ensures that the patent does not infringe on existing patents.

Q: How do court precedents influence patent evaluation? A: Court precedents provide guidance on what constitutes anticipation and non-obviousness, helping to clarify the legal standards for patent validity.

Sources

  1. US2292387A - Secret communication system.
  2. MPEP § 2131 - Anticipation — Application of 35 U.S.C. 102.
  3. USPTO - Manual of Patent Examining Procedure.

More… ↓

⤷  Subscribe

Details for Patent 7,001,602

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 December 09, 1991 7,001,602 2017-07-15
Abbvie Inc. BOTOX onabotulinumtoxina For Injection 103000 December 09, 1991 7,001,602 2017-07-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,001,602

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9903483 ⤷  Subscribe
United States of America 9066943 ⤷  Subscribe
United States of America 8840905 ⤷  Subscribe
United States of America 8062643 ⤷  Subscribe
United States of America 8057807 ⤷  Subscribe
United States of America 7968104 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.